Newsroom

  • AVEO Pharmaceuticals’ Oral, Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patients with Advanced Kidney Cancer

    Download PDF 272-Patient Phase 2 Data Show 91.7 Percent Disease Control Rate and Favorable Tolerability; Interim Results Being Presented at ASCO GU Indicate Highly Differentiated VEGFR Profile CAMBRIDGE, Mass., February 25, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced

  • AVEO Initiates Phase 1b/2a Combination Trial of Novel, Triple VEGF Receptor Inhibitor

    Download PDF CAMBRIDGE, Mass., February 19, 2009 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the initiation of a Phase 1b/2a clinical trial in breast cancer, expanding on the broad development program for its lead product candidate, the novel, oral

  • AVEO Pharmaceuticals to Present at Massachusetts Biotechnology Council

    Download PDF CAMBRIDGE, Mass., February 12, 2009 – AVEO Pharmaceuticals, Inc. today announced that M. Isabel Chiu, Ph.D., vice president, translational research, will lead a session for the Mass Biotechnology Council’s (MBC) Drug Discovery Committee on Thursday, February 19, 2009 at 8:00 a.m. EST in the MBC offices, in Cambridge, Mass. Dr. Chiu’s presentation, “AVEO’s

  • AVEO Pharmaceuticals Announces Oral Presentation of Data from AV-951 Phase 2 Clinical Trial at the 2009 Genitourinary Symposium

    Download PDF CAMBRIDGE, Mass., February 11, 2009 – AVEO Pharmaceuticals, Inc. today announced that interim safety and efficacy results from the Phase 2 clinical trial of its lead product AV-951 – a novel, highly potent and selective triple VEGF receptor inhibitor – will be presented during an oral abstract session at the 2009 Genitourinary (GU)

  • AVEO Pharmaceuticals to Present at 27th Annual J.P. Morgan Healthcare Conference

    Download PDF CAMBRIDGE, Mass., January 6, 2009– AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 11:30 a.m. PST at the Westin St. Francis Hotel in San Francisco. Mr. Ha-Ngoc is expected to

  • AVEO Pharmaceuticals to Present at the Lazard Capital Markets Fifth Annual Healthcare Conference

    Download PDF CAMBRIDGE, Mass., November 12, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Lazard Capital Markets Fifth Annual Healthcare Conference on Wednesday, November 19, 2008 at 11:30 a.m. (ET) at the St. Regis in New York City. About AVEO AVEO is

  • AVEO Pharmaceuticals to Present at First Annual Boston Biotech R&D Conference,

    Download PDF CAMBRIDGE, MA [October 20, 2008] – AVEO Pharmaceuticals today announced that Murray O. Robinson, Ph.D., senior vice president of oncology, will present at the 2008 Boston Biotech R&D Conference on Wednesday, October 22, 2008, 2:20 p.m. (ET) at Harvard Medical School. This conference will bring luminaries from top academic institutions that have been

  • AVEO Pharmaceuticals to Present at the Third Annual JMP Securities Healthcare Focus Conference

    Download PDF CAMBRIDGE, Mass., September 30, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Third Annual JMP Securities Healthcare Focus Conference on Tuesday, October 7, 2008 at 3:00 p.m. (ET) at the Le Parker Meridien in New York City. About AVEO AVEO

For media inquiries, please contact:

John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352

The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.